Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04805515 · ClinicalTrials.gov registry record · NA
Impact of Nicotine Messaging on Nicotine Beliefs and Tobacco Use Behavior
A NA study, sponsored by University of Vermont.
- Completed
- Registry status
- NA
- Development phase
- 794
- Enrollment target
NCT04805515: Completed NA study, sponsored by University of Vermont.
NCT04805515 is a NA study that has completed, run by University of Vermont. The registered enrollment target is 794 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04805515, a NA study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- NA
- Development phase
- 794 participants
- Enrollment target
Study Summary
This is a 2-arm, randomized controlled, population based trial to test the impact of multiple exposures to brief nicotine corrective messages among adult tobacco cigarette smokers and non-smokers followed in waves over 12 weeks. The primary outcome, assessed at wave 1 (baseline), wave 2 (weeks 5-6), and wave 4 (weeks 11-13) is nicotine beliefs. Secondary outcomes assessed at the same time points include intention to use nicotine/tobacco products and nicotine/tobacco use.
Primary Outcome
3 items assessing nicotine false beliefs (range 3-11), 6 items assessing nicotine replacement therapy (NRT) false beliefs (range 4-20), 4 items assessing e-cigarette false beliefs (range 2-14), 11 items assessing reduced nicotine content (RNC) cigarette false beliefs (range 14-45), and two items assessing beliefs about additive-free and organic tobacco products. Higher scale scores indicate a higher number of false beliefs.
Interventions
- BEHAVIORAL Nicotine Corrective Messages
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 794 participants |
| Start Date | 2021-02-12 |
| Est. Completion | 2021-05-31 |
| Phase | NA |
What the finished NCT04805515 record still lists
NCT04805515 is an interventional study that assigns participants to a tested intervention. The registered 794 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 1 intervention - of which Nicotine Corrective Messages is the first listed.
NCT04805515 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04805515 about?
NCT04805515 is a clinical study titled "Impact of Nicotine Messaging on Nicotine Beliefs and Tobacco Use Behavior". This is a 2-arm, randomized controlled, population based trial to test the impact of multiple exposures to brief nicotine corrective messages among adult tobacco cigarette smokers and non-smokers followed in waves over 12 weeks. The primary outcome, assessed at wave 1 (baseline), wave 2 (weeks 5-6),...
What is the current status of trial NCT04805515?
This trial is currently completed. It is a NA study. The enrollment target is 794 participants. The study started on 2021-02-12. Estimated completion is 2021-05-31.
What interventions are being tested in trial NCT04805515?
The interventions under investigation include: Nicotine Corrective Messages (BEHAVIORAL).
Who is sponsoring clinical trial NCT04805515?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04805515's enrollment target sits among peer trials
794 140th of 2000 higher than 1,861 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06208150 · 795 participants · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- NCT06724172 · 795 participants · NA
CHIME: Comparing Health Interventions for Maternal Equity
- NCT05150691 · 796 participants · Phase 1
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- NCT03424005 · 792 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI